Marina Boudin

First lock: knowledge integration

Heterogeneous data

- DrugBank
- SIDER
- PharmGKB
- Human phenotype ontology (HPO)
- NPASS (natural compounds)
- Bio2RDF

Zoom Webinar
You are viewing Marina Boudin's screen
View Options

Marina Boudin

First lock : knowledge integration

Heterogeneous data



Audio Settings
Chat
Raise Hand
Q&A
Leave

Xiaodong LI (You) 12:12 AM
Another question, since the drug candidates need to be further veridied in the lab, how to make sure that the scores obtained do help in the clinical trial. In other words, any suggestion to improve the confidence of the drugs to be recommended in addition to the score?

Marina Boudin 12:22 AM
We can look at the publications and clinical trials about those drugs. We can also use the structures of the drugs to compute the biological binding possibility of the link between the drug and the target. This technique allow us to reduce the scope of research to concentrate the investigations on leads that seems to have a great possibility to interact with precise targets.